BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30973976)

  • 1. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.
    Elavia N; Panch SR; McManus A; Bikkani T; Szymanski J; Highfill SL; Jin P; Brudno J; Kochenderfer J; Stroncek DF
    Transfusion; 2019 May; 59(5):1755-1764. PubMed ID: 30973976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
    Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
    Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.
    Stroncek DF; Lee DW; Ren J; Sabatino M; Highfill S; Khuu H; Shah NN; Kaplan RN; Fry TJ; Mackall CL
    J Transl Med; 2017 Mar; 15(1):59. PubMed ID: 28298232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
    Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
    J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
    Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
    Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T manufactured from frozen PBMC yield efficient function with prolonged
    Abraham-Miranda J; Menges M; Atkins R; Mattie M; Kanska J; Turner J; Hidalgo-Vargas MJ; Locke FL
    Front Immunol; 2022; 13():1007042. PubMed ID: 36225930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.
    Panch SR; Srivastava SK; Elavia N; McManus A; Liu S; Jin P; Highfill SL; Li X; Dagur P; Kochenderfer JN; Fry TJ; Mackall CL; Lee D; Shah NN; Stroncek DF
    Mol Ther; 2019 Jul; 27(7):1275-1285. PubMed ID: 31178392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group O plasma as a media supplement for CAR-T cells and other adoptive T-cell therapies.
    Nelson RC; Fellowes V; Jin P; Liu H; Highfill SL; Ren J; Szymanski J; Flegel WA; Stroncek DF
    Transfusion; 2020 May; 60(5):1004-1014. PubMed ID: 32167176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
    Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
    Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
    Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
    Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
    Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
    Cardle II; Cheng EL; Jensen MC; Pun SH
    Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8
    Lee SY; Lee DH; Sun W; Cervantes-Contreras F; Basom RS; Wu F; Liu S; Rai R; Mirzaei HR; O'Steen S; Green DJ; Shadman M; Till BG
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38251688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.